WO1999014238A1 - Process for the preparation of calcitonin - Google Patents
Process for the preparation of calcitonin Download PDFInfo
- Publication number
- WO1999014238A1 WO1999014238A1 PCT/KR1997/000173 KR9700173W WO9914238A1 WO 1999014238 A1 WO1999014238 A1 WO 1999014238A1 KR 9700173 W KR9700173 W KR 9700173W WO 9914238 A1 WO9914238 A1 WO 9914238A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- boc
- leu
- thr
- fragment
- ser
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/585—Calcitonins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to the peptide synthesis, especially to the 0 process for preparing calcitonin by using new side chain protected amino acids with high purity in good yield.
- Peptides can be obtained by i) extracting from natural products ii) DNA 0 recombination technique iii) chemical synthesis, among them i) and ii) have the limits, for example the low yield of active extract, the uncertainty of the identification of purity and the difficulty of the removal of impurities from microorgaism.
- the chemical synthesis have been widely used for larger scale commercial production of peptides, and in parallel with the advances in
- the former method is more likely to be used for the preparation of larger quantities and higher qualities of peptides, since i) side chains of the amino acids
- ⁇ 0 acids can be minimally protected, ii) various coupling methods can be freely choosed, iii) growing peptide can be purified at any step, iv) quantity of the reactant can be controlled unrestrictly.
- the liquid phase method has the limits on preparing the high quality of peptide largely because of i) time-consuming process, ii) possibility of the side reaction, iii) low-efficiency of the reaction due to solubility, iv) difficulty of the purification of final peptide.
- the invention provides new procedure to prepare high quality of calcitonin efficiently by liquid phase synthesis, combined with conventional segment condensation of the fragments obtained by stepwise coupling with Boc-protected amino acids using coupling agents(DCC, HOBT) or active esters.
- the invention provides new methodology for the preparation of peptide using newly developed side chain and C-terminal protecting groups, based on liquid phase synthesis.
- the object of the invention is to provide new method for obtaining calcitonin by the use of newly side chain protected amino acid derivatives or the salts having the general formula (I).
- R may represents -CH2CH2CH2CH2NH-, -CH2CO- or -CH2CH2CO-, and R may represents phenylthioethyloxyca onyl(Ptc), phenylsulfonylethyloxycarbonyl(Psc), phenylthioethyloxy(OPte) or phenylsulfonylethyloxy(OPse), and R may represents hydrogen or ⁇ -amino protecting group.
- Another object of the invention is to provide new efficient way to prepare large quantities of high quality calcitonin by means of assembly of the following fragments 1 to 7.
- Calcitonin may be illustrated as the following formula (II).
- A may represents Ala or Ser, and A may represents Asn or Ser, and A may represents Asn or Asp(OPse) (wherein Pse is phenylsulfonylethyl), and A may represents Thr or Val, and A may represents Ala or Ser;
- the invention is based on the strategy of segment condensation which has obvious advantages in the synthesis of longer peptide chain.
- This methodology has the likely racemization of the activated C-terminal residue of the carboxyl component.
- following methods are recommended; i) good selection of the activated carboxyl residue: glycine and proline are favorable, ii) controle of the reaction condition: low polarity solvent, neutral pH, low temperature, iii) appropriate selection of the mothod for activating the carboxylic acid component, iv) use of ⁇ -alkoxycarbonyl protected amino acids in the coupling reactions.
- the invention is intended to give the efficient production of calcitonin by the process, considering the points mentioned above.
- the methodology useful for larger scale synthesis of calcitonin To clarify the superiority of the invention by an embodiment, the process for preparing salmon calcitonin described below and newly developed amino acid derivatives will now be explained.
- fragments 1 1 to 71 used in the synthesis of salmon calcitonin by the segment condensation are prepared by the use of only Boc group which is common, inexpensive, and simple to blocking and deblocking, differing from the other methodologies (example: JP 6-16694A) using various groups for the temporary masking of ⁇ -amino groups. Size and number of the fragments are optimized to reduce the susceptibility of racemization; firstly, glycine or proline are selected as C-terminal residue of segments. In particular, new side chain protected amino acids are introduced to synthesize the fragments for the preparation of larger quantities and higher qualities of salmon calcitonin.
- the procedure for preparing salmon calcitonin by segment condensation based on the invention is represented in the followig diagram 1.
- Boc-R-T-N-T-G-S-G-f-P-NH 2 (24-32) H-R-T-N-T-G-S-G-T-P-NHt 2TFA(24-32)
- side chain protecting group plays important role in the design for the synthethic route of salmon calcitonin, since it contains glutamic acid with side carboxyl group and lysine with side amino group which have to be protected semipermanently till the completion of peptide chain.
- a classical approach the use of t-butyl or benzyl group for the protection of side carboxyl function of glutamic acid and of benzyloxycarbonyl(Z) or t-butyloxycarbonyl(Boc) or trityl(Trt) group for the protection of side amino function, is still practiced mainly.
- the methods for deblocking, catalytic hydrogenation and acidolysis have susceptibility of side reaction and are time consuming.
- the invention is intended to develope new base-labile side chain protecting group which is easy to introduce, stable during coupling, and readily removed under mild and selective conditions in combination with Boc used for the transient protection of the ⁇ -amino function.
- Boc used for the transient protection of the ⁇ -amino function.
- Pse and Pse groups are exploited to the protection of the side chain of glutamic acid and lysine, respectively.
- These groups without negative inductive effect from para substituent of phenyl group are stable not only under acidolysis and catalytic hydrogenation, but also under weak basic coupling condition, nevertheless these are readily removed by addition of piperidine within shorter time.
- Boc-Lys(Psc)-OH DCHA(5), Boc-Asp(OPse)-OH DCHA(8), Boc-Glu(OPse)-OH DCHA(9) are newly introduced to the synthesis of calcitonin.
- These compounds are prepared by the procedure as shown in diagram 2; ⁇ -amino function of lysine is protected by the addition of phenylthioethylchloroformate(3) whilst the ⁇ -groups are chelated to copper(ll), followed by the oxidation, ⁇ - and ⁇ -carboxyl function of aspartic and glutamic acid are blocked by the addition of phenylthioethanol, followed by oxidation.
- p-nitrophenylsulphonylethyl(Nse) group is newly employed as the masking group of C-terminal of fragment 6 and 7.
- the blocking group of C-terminal It should be considered that the group is stable under coupling and removal of the ⁇ -amino protecting group, and readily removable under mild condition, and orthogonal with the side chain protecting group, too. So, it is intended to utilize the Nse group known in the art(Samukov, V. V. Tetrahedron Lett. 35 1994, 7821 : US pat. 5,527,881 ) for protecting C-terminal, which is selectively removal by base, and stable under the acidolysis and the catalytic hydrogenation.
- the invention will now be illustrated by means of the following non limiting examples.
- FT-IR Jasco 300F.
- NMM N-methyl morpholine
- Nse p-nitrophenylsulphonylethyl OPse: phenylsulphonylethyloxy
- Pse phenylsulphonylethyl
- Ptc phenylthioethyloxycarbonyl
- C cysteine E: glutamic acid G: glysine H: histidine K: lysine L: leucine N: asparagine P: proline Q: glutamine R: arginine S: serine T: threonine V: valine Y: tyrosine
- the compound 9 as white powder was prepared by the same procedure as described in d) with an yield of 92%. m.p.: 155-157°C
- Biological active salmon calcitonin as white powder was prepared by the segment condensation as shown in diagram 1. The synthesis was started from i) the condensation of fragment 1 , the tetrapeptide corresponding to the 5 carboxamide end of the salmon calcitonin sequence, with Boc-protected fragment 2 by the conventional method using DCC and HOBT. And stepwise condensations with Boc-protected fragment 3, 4, 5 and Boc group removals were mediated by the DCC/HOBT and TFA, respectively, to give newly side chain protected docosapeptide 45 in moderate yield.
- target peptide can be prepared by using new amino acid derivatives which are very stable under coupling and deblocking with good yield and in high purity, which shows high bi logical activity.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU44009/97A AU4400997A (en) | 1997-09-18 | 1997-09-18 | Process for the preparation of calcitonin |
PCT/KR1997/000173 WO1999014238A1 (en) | 1997-09-18 | 1997-09-18 | Process for the preparation of calcitonin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR1997/000173 WO1999014238A1 (en) | 1997-09-18 | 1997-09-18 | Process for the preparation of calcitonin |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999014238A1 true WO1999014238A1 (en) | 1999-03-25 |
Family
ID=19494187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR1997/000173 WO1999014238A1 (en) | 1997-09-18 | 1997-09-18 | Process for the preparation of calcitonin |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU4400997A (en) |
WO (1) | WO1999014238A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004092202A1 (en) * | 2003-04-07 | 2004-10-28 | Novetide, Ltd. | Process for production of cyclic peptides |
CN104326944A (en) * | 2014-11-04 | 2015-02-04 | 崇州合瑞科技有限公司 | Method for preparing Boc-L-threonine |
US10875826B2 (en) | 2006-09-07 | 2020-12-29 | Emisphere Technologies, Inc. | Process for the manufacture of SNAC (salcaprozate sodium) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07188297A (en) * | 1993-12-24 | 1995-07-25 | Daicel Chem Ind Ltd | Production of peptide |
WO1997029127A1 (en) * | 1996-02-06 | 1997-08-14 | Bionebraska, Inc. | Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs |
-
1997
- 1997-09-18 WO PCT/KR1997/000173 patent/WO1999014238A1/en not_active Application Discontinuation
- 1997-09-18 AU AU44009/97A patent/AU4400997A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07188297A (en) * | 1993-12-24 | 1995-07-25 | Daicel Chem Ind Ltd | Production of peptide |
WO1997029127A1 (en) * | 1996-02-06 | 1997-08-14 | Bionebraska, Inc. | Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI ON EPOQUE, week 9542, LONDON: DERWENT PUBLICATIONS LTD., AN 95-322942, Class B04; & JP 07188297 A (DAICEL CHEM. IND., LTD). * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004092202A1 (en) * | 2003-04-07 | 2004-10-28 | Novetide, Ltd. | Process for production of cyclic peptides |
US10875826B2 (en) | 2006-09-07 | 2020-12-29 | Emisphere Technologies, Inc. | Process for the manufacture of SNAC (salcaprozate sodium) |
CN104326944A (en) * | 2014-11-04 | 2015-02-04 | 崇州合瑞科技有限公司 | Method for preparing Boc-L-threonine |
Also Published As
Publication number | Publication date |
---|---|
AU4400997A (en) | 1999-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2075878C (en) | Cyclic peptides and use thereof | |
US4116951A (en) | [Asn2 ]-thymosin α1 and analogs thereof | |
US4743677A (en) | Calcitonin gene related peptide derivatives | |
DE3782010T2 (en) | PEPTIDE DERIVATIVES DERIVED FROM THE CALCITONIN GENE. | |
DE3782073T2 (en) | SYNTHETIC ATRIAL PEPTIDES. | |
EP0552417B1 (en) | Cyclic peptides and use thereof | |
NO166532B (en) | PROCEDURE FOR PREPARING THE PEPTID H-ARG-X-Z-Y-TYR-R. | |
US5166394A (en) | Coupling reagent for peptide synthesis | |
Moroder et al. | Studies on cytochrome c. Part II. Synthesis of the protected heptapeptide (sequence 17–23) of Baker's yeast iso‐1‐cytochrome c | |
EP0292729A2 (en) | Process for solid phase peptide synthesis | |
WO1999014238A1 (en) | Process for the preparation of calcitonin | |
US4758552A (en) | Gonadoliberin derivatives containing an aromatic aminocarboxylic acid in the 6-position, pharmaceutical and veterinary compositions containing them and process for preparing same | |
Chino et al. | Generation of two isomers with the same disulfide connectivity during disulfide bond formation of human uroguanylin | |
EP0518295A2 (en) | Allyl side chain protection in peptide synthesis | |
US5965770A (en) | N-aryloxycarbonyl amino acids and peptides and their derivatives | |
US3953415A (en) | Process for the preparation of biologically active polypeptides containing aspartyl group | |
JULIANO et al. | Amino Acids and Peptides. XVI. Synthesis of NG-Tosylarginyl Peptide Derivatives-Observation of Lactam Formation of Arginyl Residue | |
US3994871A (en) | Process for the manufacture of peptides containing cystine | |
WO1999014189A1 (en) | Amino acid derivatives | |
Hase et al. | SYMMETRICAL DISULFIDE BONDS AS S‐PROTECTING GROUPS AND THEIR CLEAVAGE BY DITHIOTHREITOL: SYNTHESIS OF OXYTOCIN WITH HIGH BIOLOGICAL ACTIVITY | |
GB1590668A (en) | Process for the preparation of thymosin a1 and an analogue | |
Okada et al. | Amino acids and peptides. X. Synthesis of two dotriacontapeptides corresponding to C-terminal sequence 30–61 (fragment α) of human liver metallothionein II and their heavy metal binding properties | |
US4093609A (en) | Somatostatin synthesis | |
US4416820A (en) | Indole derivatives and a method for production of peptides | |
UCHIYAMA et al. | Studies on Secretin. I. Synthesis of Completely Protected Secretin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020007002920 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007002920 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020007002920 Country of ref document: KR |